Browsing by Author "Castellano, Joel"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Development and Validation of a Tool to Assess the Structural Quality of Palliative Care Services
    (2023) Gallastegui-Brana, Aintzane; Rodriguez-Nunez, Alfredo; Palacios, Josefa; Soto-Soto, Fernanda; Castellano, Joel; Soto-Guerreo, Sebastia; Perez-Cruz, Pedro E.
    Context. The current gap in access to palliative care requires the expansion of palliative care services worldwide. There is little information about the structural components required by palliative care services to provide adequate end-of-life care. No specific tools have been developed to assess the structural quality of these services. Objective. To develop and validate a tool to assess the structural quality of palliative care services. Methods. A scoping review of literature was performed to identify structural quality indicators of palliative care services. National experts participated in a two-round Delphi method to reach consensus regarding the importance and measurement feasibility of each proposed indicator. Consensus was reached for each indicator if 60% or more considered them both important and feasible. The selected indicators were tested among Chilean palliative care services to assess instrument psychometric characteristics. Results. Thirty-one indicators were identified. Thirty-five experts participated in a two-round Delphi survey. Twenty-one indicators reached consensus and were included in the structural quality of palliative care services tool (SQPCS-21). This instrument was applied to 201 out of 250 palliative care services in Chile. Achievement for each indicator varied between 8% and 96% (mean 52%). The total SQPCS-21 score varied between 3 and 21 points (mean 11 points). Conclusion. The SQPCS-21 tool to assess structural quality of palliative care services, has good content and construct validity and its application provides information about institutions at the individual and aggregated level. This tool can provide guidance to monitor the structural quality of palliative care worldwide. J Pain Symptom Manage 2023;65:490-499. (c) 2023 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
  • Thumbnail Image
    Item
    Is acetaminophen beneficial in patients with cancer pain who are on strong opioids? A randomized controlled trial
    (2023) Leiva, Ofelia; Letelier Saavedra, Luz María; Rojas Orellana, Luis; Viviani García, Paola; Castellano, Joel; González Candia, Antonio Felipe; Pérez Cruz, Pedro
    ContextPain is common among cancer patients. The evidence recommends using strong opioids in moderate to severe cancer pain. No conclusive evidence supports the effectiveness of adding acetaminophen to patients with cancer pain who are already using this regime.ObjectiveTo assess the analgesic efficacy of acetaminophen in hospitalized cancer patients with moderate to severe pain receiving strong opioids.MethodsIn this randomized blinded clinical trial, hospitalized cancer patients with moderate or severe acute pain managed with strong opioids were randomized to acetaminophen or placebo. The primary outcome was pain intensity difference between baseline and 48 hours using the Visual Numeric Rating Scales (VNRS). Secondary outcomes included change in morphine equivalent daily dose (MEDD), and patients’ perception of improved pain control.ResultsAmong 112 randomized patients, 56 patients received placebo, 56 acetaminophen. Mean (standard deviation (SD)) decrease in pain intensity (VNRS) at 48 hours were 2.7 (2.5) and 2.3 (2.3), respectively (95% Confidence Interval(CI) [-0.49;1.32];p=0.37). Mean (SD) change in MEDD was 13.9 (33.0) mg/day and 22.4 (57.7), respectively (95% CI [-9.24;26.1];p=0.35). The proportion of patients perceiving pain control improvement after 48 hours was 82% in the placebo and 80% in the acetaminophen arms (p=0.81).ConclusionAmong patients with cancer pain on strong opioid regime, acetaminophen may not improve pain control, or decrease total opioid use. These results add to the current evidence available suggesting not to use acetaminophen as an adjuvant for advanced cancer patients with moderate to severe cancer pain who are on strong opioids.
  • Thumbnail Image
    Item
    Púrpura trombótica trombocitopénica: descripción y análisis de 23 casos tratados en Chile entre 2017 y 2022
    (2025) Cathalifaud Zilleruelo, Daniel Hernán; Manríquez Naredo, Jean Paul Bastián; Rodríguez Cáceres, Benjamín Bastián; Eymin Lago, Gonzalo; Sanfuentes Diez, Benjamín Andrés; Castellano, Joel; Valenzuela Suárez, Andrés Daniel
    Introducción: Desde la primera descripción de la púrpura trombótica trombocitopénica, causada por una deficiencia severa de ADAMTS13, el procedimiento de plasmaféresis y la inmunosupresión se han instaurado como estándares de tratamiento, permitiendo disminuir su elevada mortalidad. Los registros prospectivos de esta afección han proporcionado información valiosa sobre su fisiopatología, presentación clínica y desenlaces. El objetivo de este estudio es actualizar la experiencia local chilena sobre el diagnóstico y manejo de esta enfermedad, mediante una serie de casos de pacientes atendidos entre 2017 y 2022. Métodos: Estudio tipo serie de casos que incluyó pacientes mayores de 18 años diagnosticados con púrpura trombótica trombocitopénica, atendidos entre junio de 2017 y agosto de 2022, en el Hospital Clínico UC Christus. Se recolectó información desde registros clínicos, que se utilizaron para describir la cohorte y cálculos estadísticos. Para la descripción de desenlaces se utilizaron las definiciones aceptadas en la literatura. Resultados: Nuestra serie presentó pacientes de mayor edad y prevalencia de comorbilidades que las reportadas en la literatura. Las manifestaciones clínicas más importantes incluyeron síntomas constitucionales, gastrointestinales, hemorragíparos y neurológicos, con frecuencias de presentación distintas a las descritas internacionalmente. Encontramos una menor capacidad del puntaje PLASMIC para la pesquisa de casos de púrpura trombótica trombocitopénica en nuestra serie. La estrategia terapéutica predominante fue la combinación de glucocorticoides y plasmaféresis (61% de los pacientes). Hubo una alta tasa de mortalidad (56,5%) y eventos adversos relacionados con plasmaféresis, especialmente infecciones asociadas a su uso. Conclusiones: Este estudio destaca los desafíos diagnósticos y terapéuticos de la púrpura trombótica trombocitopénica en el contexto local. Asimismo, releva la necesidad de mejorar nuestras estrategias de manejo mediante la estandarización del cuidado y de una mejor aplicación de las guías clínicas con el objeto de disminuir la elevada mortalidad en estos pacientes.
  • Thumbnail Image
    Item
    Randomized double-blind controlled trial to assess the efcacy of intravenous acetaminophen associated with strong opioids in the treatment of acute pain in adult cancer patients: study protocol
    (2022) Leiva, Ofelia; Castellano, Joel; Letelier Saavedra, Luz María; Rojas Orellana, Luis; Viviani García, Paola; González Candia, Antonio Felipe; Pérez Cruz, Pedro
    Background: Cancer pain is one of the most frequent and relevant symptoms in cancer patients and impacts on patient’s quality of life. International and local standards recommend as an initial strategy the use of an analgesic scheme composed of strong opioids associated with adjuvants such as acetaminophen, based upon the assumption that combining drugs could have a better analgesic effect, could allow lowering opioid dosing, and could prevent the occurrence of adverse effects of opioids. However, there is uncertainty about the impact of acetaminophen as an adjuvant in patients who use strong opioids for moderate to severe pain management in cancer patients. The aim of this study is to assess the efficacy and safety of intravenous acetaminophen associated with strong opioids in hospitalized adult cancer patients who have moderate to severe cancer-related pain. Methods: We will perform a randomized double-blinded controlled study comparing intravenous acetaminophen 1 g 4 times a day versus placebo for 48 h as an adjuvant to strong opioids. We will assess pain intensity as a primary outcome, using the verbal numerical rating scale (VNRS, I0 to 10 scale with higher scores meaning higher pain intensity), and we will compare the mean difference in pain intensity between baseline and 48 h among the placebo and intervention groups. We estimate that a decrease of 1 point in the VNRS would be clinically significant. Assuming a standard deviation in pain intensity of 1.7 points, an alpha of 0.025, and a power of 0.8, we estimate a sample size of 112 patients, with 56 patients in each arm. Secondary outcomes include the difference in total opioid use between baseline and at 48 h among the groups, and adverse effects such as drowsiness, constipation, nausea, and vomiting would be evaluated. Discussion: The randomized, double-blind, placebo-controlled design is the best strategy to assess the efficacy of acetaminophen as an adjuvant in adult cancer patients with moderate to severe pain who are receiving strong opioids. We expect to contribute to national and international guidelines with these results.